Startups · 2026-10-271 min read

Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute

Plaaslike outomatiese vertaling · Oorspronklike brontaal

Illustration generated by Business News; it is not a source photograph.

Opsomming

OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…

Oorspronklike brontaal: PR Newswire UK — News ReleasesLees oorspronklike →